156 related articles for article (PubMed ID: 27317737)
1. Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib.
Patchett N; Furlan A; Marsh JW
Jpn J Clin Oncol; 2016 Sep; 46(9):839-44. PubMed ID: 27317737
[TBL] [Abstract][Full Text] [Related]
2. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
[TBL] [Abstract][Full Text] [Related]
3. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
Ronot M; Bouattour M; Wassermann J; Bruno O; Dreyer C; Larroque B; Castera L; Vilgrain V; Belghiti J; Raymond E; Faivre S
Oncologist; 2014 Apr; 19(4):394-402. PubMed ID: 24652387
[TBL] [Abstract][Full Text] [Related]
4. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
Meyer T; Palmer DH; Cheng AL; Hocke J; Loembé AB; Yen CJ
Liver Int; 2017 Jul; 37(7):1047-1055. PubMed ID: 28066978
[TBL] [Abstract][Full Text] [Related]
5. Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib.
Mulé S; Thiefin G; Costentin C; Durot C; Rahmouni A; Luciani A; Hoeffel C
Radiology; 2018 Aug; 288(2):445-455. PubMed ID: 29584597
[TBL] [Abstract][Full Text] [Related]
6. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma treated with sorafenib: Arterial tumor perfusion in dynamic contrast-enhanced CT as early imaging biomarkers for survival.
Nakamura Y; Kawaoka T; Higaki T; Fukumoto W; Honda Y; Iida M; Fujioka C; Kiguchi M; Aikata H; Chayama K; Awai K
Eur J Radiol; 2018 Jan; 98():41-49. PubMed ID: 29279169
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.
Salvaggio G; Furlan A; Agnello F; Cabibbo G; Marin D; Giannitrapani L; Genco C; Midiri M; Lagalla R; Brancatelli G
Radiol Med; 2014 Apr; 119(4):215-21. PubMed ID: 24297581
[TBL] [Abstract][Full Text] [Related]
9. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
Takada J; Hidaka H; Nakazawa T; Kondo M; Numata K; Tanaka K; Matsunaga K; Okuse C; Kobayashi S; Morimoto M; Ohkawa S; Koizumi W
BMC Res Notes; 2015 Oct; 8():609. PubMed ID: 26502722
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up.
Kaufmann S; Thaiss WM; Schulze M; Bitzer M; Lauer U; Nikolaou K; Horger M
Acta Radiol; 2018 Jul; 59(7):765-772. PubMed ID: 28927298
[TBL] [Abstract][Full Text] [Related]
11. Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma.
Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
Dig Dis; 2014; 32(6):733-9. PubMed ID: 25376291
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study.
Shiozawa K; Watanabe M; Kikuchi Y; Kudo T; Maruyama K; Sumino Y
World J Gastroenterol; 2012 Oct; 18(40):5753-8. PubMed ID: 23155317
[TBL] [Abstract][Full Text] [Related]
13. CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib.
Colagrande S; Calistri L; Campani C; Dragoni G; Lorini C; Nardi C; Castellani A; Marra F
Eur Radiol; 2021 Mar; 31(3):1608-1619. PubMed ID: 32827266
[TBL] [Abstract][Full Text] [Related]
14. Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma.
Kim MJ; Choi JI; Lee JS; Park JW
J Gastroenterol Hepatol; 2011 Jul; 26(7):1201-6. PubMed ID: 21371120
[TBL] [Abstract][Full Text] [Related]
15. Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.
Tovoli F; Renzulli M; Negrini G; Brocchi S; Ferrarini A; Andreone A; Benevento F; Golfieri R; Morselli-Labate AM; Mastroroberto M; Badea RI; Piscaglia F
Eur Radiol; 2018 Sep; 28(9):3611-3620. PubMed ID: 29633000
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
[TBL] [Abstract][Full Text] [Related]
17. Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.
Takeda H; Nishikawa H; Osaki Y; Tsuchiya K; Joko K; Ogawa C; Taniguchi H; Orito E; Uchida Y; Izumi N;
Liver Int; 2015 May; 35(5):1581-9. PubMed ID: 24836552
[TBL] [Abstract][Full Text] [Related]
18. Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma.
Kuzuya T; Ishigami M; Ishizu Y; Honda T; Hayashi K; Katano Y; Hirooka Y; Ishikawa T; Nakano I; Goto H
PLoS One; 2015; 10(9):e0138776. PubMed ID: 26421430
[TBL] [Abstract][Full Text] [Related]
19. Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib.
Dai X; Schlemmer HP; Schmidt B; Höh K; Xu K; Ganten TM; Ganten MK
Eur J Radiol; 2013 Feb; 82(2):327-34. PubMed ID: 23246016
[TBL] [Abstract][Full Text] [Related]
20. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.
Zocco MA; Garcovich M; Lupascu A; Di Stasio E; Roccarina D; Annicchiarico BE; Riccardi L; Ainora ME; Ponziani F; Caracciolo G; Rapaccini GL; Landolfi R; Siciliano M; Pompili M; Gasbarrini A
J Hepatol; 2013 Nov; 59(5):1014-21. PubMed ID: 23811306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
